|






 |
Publications (selected, from 2000 to present)
|
Cominelli F. |
|
Cytokine-based therapies for Crohn's
disease--new paradigms.
N Engl J
Med. 2004 Nov 11;351(20):2045-8. |
|
Bickston SJ, Cominelli F. |
|
Optimal dosing of 5-aminosalicylic acid: 5
decades of choosing between politicians.
Clin Gastroenterol Hepatol. 2003 Jan;1(1):3-4.
|
|
Bamias G, Martin C 3rd, Marini M, Hoang S, Mishina M, Ross WG,
Sachedina MA, Friel CM, Mize J, Bickston SJ, Pizarro TT, Wei P,
Cominelli F. |
|
Expression, localization, and functional
activity of TL1A, a novel Th1-polarizing cytokine in
inflammatory bowel disease.
J Immunol.
2003 Nov 1;171(9):4868-74. |
|
Bickston SJ, Cominelli F. |
|
Recombinant interleukin 10 for the treatment of
active Crohn's disease: lessons in biologic therapy.
Gastroenterology. 2000 Dec;119(6):1781-3. |
|
Pizarro TT, Arseneau KO, Cominelli F. |
|
Lessons from genetically engineered animal
models XI. Novel mouse models to study pathogenic mechanisms of
Crohn's disease.
Am J Physiol Gastrointest Liver Physiol. 2000
May;278(5):G665-9. |
|